ArticleJournal of viral hepatitis2014
Development and evaluation of a baseline-event-anticipation score for hepatitis delta.
Article in Journal of viral hepatitis, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 70 citations in OpenAlex.
- Estimating the Global Prevalence, Disease Progression, and Clinical Outcome of Hepatitis Delta Virus Infection.The Journal of infectious diseases · 2020Pooled it
- Recommendations for treatment of viral hepatitis B in 2026 by the Polish Group of Experts for HBV.Clinical and experimental hepatology · 2026Review
- Review
- Identifying Risk Factors for Hepatocellular Carcinoma in Patients With Delta Hepatitis: A Prognostic Study.Journal of viral hepatitis · 2025Article
- Severe Liver-Related Outcomes in Patients With Hepatitis Delta: Results From a Multi-Ethnic Multicenter Long-Term Follow-Up Study.Journal of viral hepatitis · 2025Article
- Molecular Epidemiology of Hepatitis D Virus in the North-East Region of Romania.Pathogens (Basel, Switzerland) · 2024Article
- Long-Term Treatment with Bulevirtide in Patients with Chronic Hepatitis D and Advanced Chronic Liver Disease.Canadian journal of gastroenterology & hepatology · 2024Article
- An Insight Into the Factors Affecting the Prevalence and Natural History of Hepatitis D.Cureus · 2023Review
- Hepatitis Delta Infection: A Clinical Review.Seminars in liver disease · 2023Review
- Treating hepatitis D with bulevirtide - Real-world experience from 114 patients.JHEP reports : innovation in hepatology · 2023Article
- Hepatitis D Virus and Hepatocellular Carcinoma.Viruses · 2021Review
- HDV Pathogenesis: Unravelling Ariadne's Thread.Viruses · 2021Review
- Article
- Chronic hepatitis delta: A state-of-the-art review and new therapies.World journal of gastroenterology · 2019Review
- [Chronic hepatitis B and D (delta) : Current and future treatments].Der Internist · 2018Review
- Management of Hepatitis B Virus Infection: 2018 Guidelines from the Canadian Association for the Study of Liver Disease and Association of Medical Microbiology and Infectious Disease Canada.Canadian liver journal · 2018Article
- Serum cholinesterase: A predictive biomarker of hepatic reserves in chronic hepatitis D.World journal of hepatology · 2017Article
- [Personalized treatment of viral hepatitis of the present and the future : Hepatitis B, C, delta, and E].Der Internist · 2017Review
- Article
- Management of HBV and HBV/HDV-Associated Liver Cirrhosis.Visceral medicine · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis delta is considered the most severe form of viral hepatitis, but variables associated with disease progression are poorly defined. This study aimed to identify risk factors associated with worse clinical outcome in patients with hepatitis delta and to develop a clinical score to determine their risk of experiencing liver-related morbidity or mortality. We followed 75 HBsAg-anti-HDV-positive patients with hepatitis delta for up to 16 years (median 5 years). The baseline-event-anticipation score (BEA score) was developed based on variables associated with the development of liver-related clinical complications. Age, region of origin, presence of cirrhosis, albumin, INR, hyperbilirubinemia and thrombocytopenia were all associated with the development of an event in the training cohort. The BEA score included age, sex, region of origin, bilirubin, platelets and INR. Points were allocated according to hazard ratios, and three risk groups were defined: BEA-A mild risk, BEA-B moderate risk and BEA-C high risk. Hazard ratios of BEA-B and BEA-C patients for liver-related clinical endpoints were 9.01 and 25.27 vs BEA-A with an area under curve of the receiving operating characteristic curve of 0.88. The accuracy of the BEA score was confirmed in two independent validation cohorts followed in Barcelona (n = 77) and Düsseldorf (n = 62). Delta hepatitis is associated with a very severe long-term outcome. The BEA score is easy to apply and predicts with a very high accuracy the development of liver-related complications in patients with hepatitis delta.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.